MEIP
Price:
$2.41
Market Cap:
$16.06M
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical tr...[Read more]
Industry
Biotechnology
IPO Date
2003-12-18
Stock Exchange
NASDAQ
Ticker
MEIP
According to MEI Pharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.66. This represents a change of 33.50% compared to the average of 7.24 of the last 4 quarters.
The mean historical Current Ratio of MEI Pharma, Inc. over the last ten years is 8.32. The current 9.66 Current Ratio has changed 11.51% with respect to the historical average. Over the past ten years (40 quarters), MEIP's Current Ratio was at its highest in in the September 2018 quarter at 19.74. The Current Ratio was at its lowest in in the September 2016 quarter at 3.52.
Average
8.32
Median
7.66
Minimum
4.88
Maximum
13.23
Discovering the peaks and valleys of MEI Pharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 55.77%
Maximum Annual Current Ratio = 13.23
Minimum Annual Increase = -56.56%
Minimum Annual Current Ratio = 4.88
Year | Current Ratio | Change |
---|---|---|
2024 | 4.88 | -7.70% |
2023 | 5.29 | -22.68% |
2022 | 6.84 | 25.67% |
2021 | 5.44 | -39.23% |
2020 | 8.95 | 55.77% |
2019 | 5.75 | -56.56% |
2018 | 13.23 | 16.38% |
2017 | 11.37 | 34.05% |
2016 | 8.48 | -34.57% |
2015 | 12.96 | 21.39% |
The current Current Ratio of MEI Pharma, Inc. (MEIP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
5.67
5-year avg
6.28
10-year avg
8.32
MEI Pharma, Inc.’s Current Ratio is less than Magenta Therapeutics, Inc. (14.64), greater than Kezar Life Sciences, Inc. (7.65), greater than Vincerx Pharma, Inc. (2.17), greater than Avenue Therapeutics, Inc. (2.70), greater than Assembly Biosciences, Inc. (2.36), less than Neoleukin Therapeutics, Inc. (15.33), less than Instil Bio, Inc. (12.90), greater than CytomX Therapeutics, Inc. (1.04), greater than Achilles Therapeutics plc (6.04), less than Ocular Therapeutix, Inc. (13.01), greater than Spero Therapeutics, Inc. (2.68), less than Acumen Pharmaceuticals, Inc. (10.43), greater than HOOKIPA Pharma Inc. (3.26), less than Day One Biopharmaceuticals, Inc. (14.62), greater than Inozyme Pharma, Inc. (7.68), less than Terns Pharmaceuticals, Inc. (32.99), greater than Revelation Biosciences, Inc. (1.64), less than Zura Bio Limited (10.36), greater than Phio Pharmaceuticals Corp. (6.38), less than ZyVersa Therapeutics, Inc. (33.83), greater than TransCode Therapeutics, Inc. (1.58),
Company | Current Ratio | Market cap |
---|---|---|
14.64 | $42.44M | |
7.65 | $48.88M | |
2.17 | $6.49M | |
2.70 | $3.64M | |
2.36 | $97.09M | |
15.33 | $8.20M | |
12.90 | $141.29M | |
1.04 | $84.91M | |
6.04 | $46.60M | |
13.01 | $1.34B | |
2.68 | $51.87M | |
10.43 | $109.35M | |
3.26 | $18.05M | |
14.62 | $1.29B | |
7.68 | $192.08M | |
32.99 | $492.65M | |
1.64 | $3.00M | |
10.36 | $171.07M | |
6.38 | $2.98M | |
33.83 | $2.72M | |
1.58 | $2.46M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MEI Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MEI Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is MEI Pharma, Inc.'s Current Ratio?
How is the Current Ratio calculated for MEI Pharma, Inc. (MEIP)?
What is the highest Current Ratio for MEI Pharma, Inc. (MEIP)?
What is the 3-year average Current Ratio for MEI Pharma, Inc. (MEIP)?
What is the 5-year average Current Ratio for MEI Pharma, Inc. (MEIP)?
How does the current Current Ratio for MEI Pharma, Inc. (MEIP) compare to its historical average?